| Experimental Factor Ontology (EFO) Information | |
| Identifier | EFO_0010821 |
| Description | A quantification of the fat content of the liver such as liver fat fraction, typically assessed by MRI. | Trait category |
Other measurement
|
| Mapped term | PMID:32766472 |
| Polygenic Score ID & Name | PGS Publication ID (PGP) | Reported Trait | Mapped Trait(s) (Ontology) | Number of Variants |
Ancestry distribution GWAS Dev Eval |
Scoring File (FTP Link) |
|---|---|---|---|---|---|---|
| PGS000865 (PRS-HFC) |
PGP000212 | Dongiovanni P et al. J Intern Med (2017) |
Hepatic fat content | liver fat measurement | 4 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000865/ScoringFiles/PGS000865.txt.gz | |
| PGS000866 (PRS-HFC_SOS) |
PGP000212 | Dongiovanni P et al. J Intern Med (2017) |
Hepatic fat content | liver fat measurement | 4 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000866/ScoringFiles/PGS000866.txt.gz | |
| PGS002245 (PGS8_LF) |
PGP000273 | Haas ME et al. Cell Genom (2021) |
Liver fat (MRI-derived) | liver fat measurement | 8 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002245/ScoringFiles/PGS002245.txt.gz |
| PGS019999 (GRSLF) |
PGP000856 | Frostdahl H et al. Sci Rep (2024) |
Liver fat content | liver fat measurement | 10 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS019999/ScoringFiles/PGS019999.txt.gz |
|
PGS Performance Metric ID (PPM) |
Evaluated Score |
PGS Sample Set ID (PSS) |
Performance Source | Trait |
PGS Effect Sizes (per SD change) |
Classification Metrics | Other Metrics | Covariates Included in the Model |
PGS Performance: Other Relevant Information |
|---|---|---|---|---|---|---|---|---|---|
| PPM002444 | PGS000865 (PRS-HFC) |
PSS001102| European Ancestry| 356,820 individuals |
PGP000215 | Bianco C et al. J Hepatol (2020) |Ext. |
Reported Trait: Hepatocellular carcinoma in individuals with no cirrhosis | OR: 1.8 [1.1, 3.1] | AUROC: 0.55 | — | Age, sex, body mass index, type 2 diabetes, PCs(1-10), array batch, assessment centre | PRS-HFC was treated as a binary variable with a cutoff of ≥0.532 |
| PPM002434 | PGS000865 (PRS-HFC) |
PSS001094| European Ancestry| 2,564 individuals |
PGP000215 | Bianco C et al. J Hepatol (2020) |Ext. |
Reported Trait: Fatty liver disease | OR: 8.4 [5.7, 12.5] | — | — | — | — |
| PPM002423 | PGS000865 (PRS-HFC) |
PSS001096| European Ancestry| 364,048 individuals |
PGP000215 | Bianco C et al. J Hepatol (2020) |Ext. |
Reported Trait: Cirrhosis | OR: 4.1 [3.2, 5.1] | — | — | — | — |
| PPM002424 | PGS000865 (PRS-HFC) |
PSS001100| European Ancestry| 358,314 individuals |
PGP000215 | Bianco C et al. J Hepatol (2020) |Ext. |
Reported Trait: Hepatocellular carcinoma | OR: 11.1 [6.1, 20.4] | — | — | — | — |
| PPM002425 | PGS000865 (PRS-HFC) |
PSS001096| European Ancestry| 364,048 individuals |
PGP000215 | Bianco C et al. J Hepatol (2020) |Ext. |
Reported Trait: Cirrhosis | OR: 4.2 [3.3, 5.3] | — | — | Age, sex, body mass index, type 2 diabetes, PCs(1-10), array batch, assessment centre | — |
| PPM002426 | PGS000865 (PRS-HFC) |
PSS001096| European Ancestry| 364,048 individuals |
PGP000215 | Bianco C et al. J Hepatol (2020) |Ext. |
Reported Trait: Hepatocellular carcinoma | OR: 11.1 [6.1, 20.2] | — | — | Age, sex, body mass index, type 2 diabetes, PCs(1-10), array batch, assessment centre | — |
| PPM002427 | PGS000865 (PRS-HFC) |
PSS001096| European Ancestry| 364,048 individuals |
PGP000215 | Bianco C et al. J Hepatol (2020) |Ext. |
Reported Trait: Hepatocellular carcinoma | OR: 4.6 [2.5, 8.6] | — | — | Age, sex, body mass index, type 2 diabetes, PCs(1-10), array batch, assessment centre, diagnosis of cirrhosis | — |
| PPM002435 | PGS000865 (PRS-HFC) |
PSS001094| European Ancestry| 2,564 individuals |
PGP000215 | Bianco C et al. J Hepatol (2020) |Ext. |
Reported Trait: Severe fibrosis in individuals within stage F3-F4 of fatty liver disease | OR: 11.4 [7.4, 17.7] | — | — | — | — |
| PPM002436 | PGS000865 (PRS-HFC) |
PSS001094| European Ancestry| 2,564 individuals |
PGP000215 | Bianco C et al. J Hepatol (2020) |Ext. |
Reported Trait: Hepatocellular carcinoma | OR: 9.2 [5.2, 16.3] | — | — | — | — |
| PPM002437 | PGS000865 (PRS-HFC) |
PSS001094| European Ancestry| 2,564 individuals |
PGP000215 | Bianco C et al. J Hepatol (2020) |Ext. |
Reported Trait: Fatty liver disease | OR: 10.1 [6.2, 16.5] | — | — | Age, sex, body mass index, type 2 diabetes | — |
| PPM002438 | PGS000865 (PRS-HFC) |
PSS001094| European Ancestry| 2,564 individuals |
PGP000215 | Bianco C et al. J Hepatol (2020) |Ext. |
Reported Trait: Severe fibrosis in individuals within stage F3-F4 of fatty liver disease | OR: 7.5 [4.3, 13.0] | — | — | Age, sex, body mass index, type 2 diabetes | — |
| PPM002439 | PGS000865 (PRS-HFC) |
PSS001094| European Ancestry| 2,564 individuals |
PGP000215 | Bianco C et al. J Hepatol (2020) |Ext. |
Reported Trait: Hepatocellular carcinoma | OR: 3.0 [1.4, 6.4] | — | — | Age, sex, body mass index, type 2 diabetes | — |
| PPM002441 | PGS000865 (PRS-HFC) |
PSS001094| European Ancestry| 2,564 individuals |
PGP000215 | Bianco C et al. J Hepatol (2020) |Ext. |
Reported Trait: Hepatocellular carcinoma | OR: 3.0 [2.2, 3.9] | AUROC: 0.64 | — | Age, sex, body mass index, type 2 diabetes | — |
| PPM002442 | PGS000865 (PRS-HFC) |
PSS001100| European Ancestry| 358,314 individuals |
PGP000215 | Bianco C et al. J Hepatol (2020) |Ext. |
Reported Trait: Hepatocellular carcinoma | OR: 3.3 [2.4, 4.5] | AUROC: 0.63 | — | Age, sex, body mass index, type 2 diabetes, PCs(1-10), array batch, assessment centre | PRS-HFC was treated as a binary variable with a cutoff of ≥0.532 |
| PPM002446 | PGS000865 (PRS-HFC) |
PSS001099| European Ancestry| 86,204 individuals |
PGP000215 | Bianco C et al. J Hepatol (2020) |Ext. |
Reported Trait: Hepatocellular carcinoma in individuals with a body mass index ≥30 | OR: 5.2 [3.4, 8.1] | AUROC: 0.69 | — | Age, sex, body mass index, type 2 diabetes, PCs(1-10), array batch, assessment centre | PRS-HFC was treated as a binary variable with a cutoff of ≥0.532 |
| PPM002448 | PGS000865 (PRS-HFC) |
PSS001104| European Ancestry| 25,132 individuals |
PGP000215 | Bianco C et al. J Hepatol (2020) |Ext. |
Reported Trait: Hepatocellular carcinoma in individuals with type 2 diabetes | OR: 4.4 [2.7, 6.9] | AUROC: 0.7 | — | Age, sex, body mass index, type 2 diabetes, PCs(1-10), array batch, assessment centre | PRS-HFC was treated as a binary variable with a cutoff of ≥0.532 |
| PPM002450 | PGS000865 (PRS-HFC) |
PSS001095| Ancestry Not Reported| 429 individuals |
PGP000215 | Bianco C et al. J Hepatol (2020) |Ext. |
Reported Trait: Hepatocellular carcinoma | OR: 8.68 [3.2, 23.5] | AUROC: 0.64 | — | — | — |
| PPM002408 | PGS000865 (PRS-HFC) |
PSS001089| Multi-ancestry (including European)| 4,570 individuals |
PGP000212 | Dongiovanni P et al. J Intern Med (2017) |
Reported Trait: Steatosis | — | — | R²: 0.035 | — | Only 4,455 of the 4,570 individuals from DaHS were utilised as they had available genotype, phenotype and covariate data. |
| PPM002409 | PGS000865 (PRS-HFC) |
PSS001089| Multi-ancestry (including European)| 4,570 individuals |
PGP000212 | Dongiovanni P et al. J Intern Med (2017) |
Reported Trait: Alanine aminotransferase levels | — | — | Association p-value (<): 0.001 | Age, sex, ethnicity, body mass index, statin use | Only 4,455 of the 4,570 individuals from DaHS were utilised as they had available genotype, phenotype and covariate data. |
| PPM002454 | PGS000865 (PRS-HFC) |
PSS001095| Ancestry Not Reported| 429 individuals |
PGP000215 | Bianco C et al. J Hepatol (2020) |Ext. |
Reported Trait: Hepatocellular carcinoma | OR: 2.32 [1.16, 4.66] | — | — | — | PRS-HFC was treated as a binary variable with a cutoff of ≥0.532 |
| PPM002473 | PGS000865 (PRS-HFC) |
PSS001114| European Ancestry| 266,687 individuals |
PGP000217 | De Vincentis A et al. Clin Gastroenterol Hepatol (2021) |Ext. |
Reported Trait: Incident severe liver disease | HR: 1.25 [1.16, 1.35] | — | Hazard Ratio (HR, top 25% vs bottom 25%): 1.63 [1.28, 2.08] | Age, sex | — |
| PPM002474 | PGS000865 (PRS-HFC) |
PSS001115| European Ancestry| 13,268 individuals |
PGP000217 | De Vincentis A et al. Clin Gastroenterol Hepatol (2021) |Ext. |
Reported Trait: Incident severe liver disease in individuals with diabetes | HR: 1.55 [1.33, 1.8] | — | Hazard Ratio (HR, top 25% vs bottom 25%): 3.24 [1.93, 5.43] | Age, sex | — |
| PPM002475 | PGS000865 (PRS-HFC) |
PSS001116| European Ancestry| 64,655 individuals |
PGP000217 | De Vincentis A et al. Clin Gastroenterol Hepatol (2021) |Ext. |
Reported Trait: Incident severe liver disease in obese individuals | HR: 1.4 [1.25, 1.57] | — | Hazard Ratio (HR, top 25% vs bottom 25%): 2.29 [1.6, 3.29] | Age, sex | — |
| PPM002476 | PGS000865 (PRS-HFC) |
PSS001114| European Ancestry| 266,687 individuals |
PGP000217 | De Vincentis A et al. Clin Gastroenterol Hepatol (2021) |Ext. |
Reported Trait: Incident severe liver disease in individuals with a fatty liver index ≥ 60 | HR: 1.34 [1.23, 1.47] | — | Hazard Ratio (HR, top 25% vs bottom 25%): 2.13 [1.57, 2.89] | Age, sex | — |
| PPM002452 | PGS000865 (PRS-HFC) |
PSS001095| Ancestry Not Reported| 429 individuals |
PGP000215 | Bianco C et al. J Hepatol (2020) |Ext. |
Reported Trait: Hepatocellular carcinoma | OR: 6.56 [1.54, 17.39] | — | — | Age, sex, body mass index, type 2 diabetes | — |
| PPM002410 | PGS000866 (PRS-HFC_SOS) |
PSS001090| European Ancestry| 3,329 individuals |
PGP000212 | Dongiovanni P et al. J Intern Med (2017) |
Reported Trait: Alanine aminotransferase levels | — | — | Association p-value (<): 1.00e-14 | Age, sex, ethnicity, body mass index, statin use | — |
| PPM012775 | PGS002245 (PGS8_LF) |
PSS009552| European Ancestry| 361,852 individuals |
PGP000273 | Haas ME et al. Cell Genom (2021) |
Reported Trait: Incident non alcoholic fatty liver disease | HR: 1.33 [1.27, 1.39] | C-index: 0.598 [0.584, 0.612] | — | age, age squared, sex, genotyping array, 10 principal components of ancestry | — |
| PPM012776 | PGS002245 (PGS8_LF) |
PSS009553| European Ancestry| 361,852 individuals |
PGP000273 | Haas ME et al. Cell Genom (2021) |
Reported Trait: Incident non alcoholic steatohepatitis | HR: 1.67 [1.48, 1.87] | C-index: 0.684 | — | age, age squared, sex, genotyping array, 10 principal components of ancestry | — |
| PPM012777 | PGS002245 (PGS8_LF) |
PSS009554| European Ancestry| 361,852 individuals |
PGP000273 | Haas ME et al. Cell Genom (2021) |
Reported Trait: Incident cirrhosis | HR: 1.41 [1.33, 1.5] | C-index: 0.694 | — | age, age squared, sex, genotyping array, 10 principal components of ancestry | — |
| PPM012778 | PGS002245 (PGS8_LF) |
PSS009551| European Ancestry| 361,852 individuals |
PGP000273 | Haas ME et al. Cell Genom (2021) |
Reported Trait: Incident hepatocellular carcinoma | HR: 1.72 | C-index: 0.77 | — | age, age squared, sex, genotyping array, 10 principal components of ancestry | — |
| PPM038255 | PGS019999 (GRSLF) |
PSS013895| European Ancestry| 11,120 individuals |
PGP000856 | Frostdahl H et al. Sci Rep (2024) |
Reported Trait: Liver fat content in moderate physical activity group | — | — | Beta per 1-point higher GRSLF: 0.059 [0.048, 0.069] | genotyping array, first 20 genetic principal components, age, sex, alcohol consumption (g/day), smoking status, Townsend deprivation index | Effect estimate is per 1-point increase in the unweighted GRS, not per SD. |
| PPM038256 | PGS019999 (GRSLF) |
PSS013893| European Ancestry| 9,105 individuals |
PGP000856 | Frostdahl H et al. Sci Rep (2024) |
Reported Trait: Liver fat content in high physical activity group | — | — | Beta per 1-point higher GRSLF: 0.065 [0.054, 0.077] | genotyping array, first 20 genetic principal components, age, sex, alcohol consumption (g/day), smoking status, Townsend deprivation index | Effect estimate is per 1-point increase in the unweighted GRS, not per SD. |
| PPM038261 | PGS019999 (GRSLF) |
PSS013889| European Ancestry| 239,308 individuals |
PGP000856 | Frostdahl H et al. Sci Rep (2024) |
Reported Trait: Metabolic dysfunction-associated steatotic liver disease | — | — | OR per 1-point higher GRSLF: 1.17 [1.08, 1.27] | age, sex, genotyping array, and population substructure | Effect estimate is per 1-point increase in the unweighted GRS, not per SD. |
| PPM038262 | PGS019999 (GRSLF) |
PSS013889| European Ancestry| 239,308 individuals |
PGP000856 | Frostdahl H et al. Sci Rep (2024) |
Reported Trait: Chronic liver disease | — | — | OR per 1-point higher GRSLF: 1.18 [1.11, 1.24] | age, sex, genotyping array, and population substructure | Effect estimate is per 1-point increase in the unweighted GRS, not per SD. |
| PPM038263 | PGS019999 (GRSLF) |
PSS013891| European Ancestry| 28,253 individuals |
PGP000856 | Frostdahl H et al. Sci Rep (2024) |
Reported Trait: Metabolic dysfunction-associated steatotic liver disease in low physical activity group | — | — | OR per 1-point higher GRSLF: 1.07 [0.8, 1.42] p: 0.669 beta per 1-point higher GRSLF: 0.004 [-0.012, 0.021] p: 0.626 |
age, sex, first 20 genetic principal components, genotyping array, alcohol consumption (g/day), smoking status, Townsend deprivation index | Betas and CI limits were multiplied by 100 and reported as percentages in the manuscript. |
| PPM038264 | PGS019999 (GRSLF) |
PSS013892| European Ancestry| 112,364 individuals |
PGP000856 | Frostdahl H et al. Sci Rep (2024) |
Reported Trait: Metabolic dysfunction-associated steatotic liver disease in moderate physical activity group | — | — | OR per 1-point higher GRSLF: 1.11 [0.97, 1.27] p: 0.119 beta per 1-point higher GRSLF: 0.008 [-0.004, 0.02] p: 0.211 |
age, sex, first 20 genetic principal components, genotyping array, alcohol consumption (g/day), smoking status, Townsend deprivation index | Betas and CI limits were multiplied by 100 and reported as percentages in the manuscript. |
| PPM038265 | PGS019999 (GRSLF) |
PSS013890| European Ancestry| 98,691 individuals |
PGP000856 | Frostdahl H et al. Sci Rep (2024) |
Reported Trait: Metabolic dysfunction-associated steatotic liver disease in high physical activity group | — | — | OR per 1-point higher GRSLF: 1.41 [1.15, 1.73] p: 0.001 beta per 1-point higher GRSLF: 0.012 [0.003, 0.021] p: 0.008 |
age, sex, first 20 genetic principal components, genotyping array, alcohol consumption (g/day), smoking status, Townsend deprivation index | Betas and CI limits were multiplied by 100 and reported as percentages in the manuscript. |
| PPM038266 | PGS019999 (GRSLF) |
PSS013891| European Ancestry| 28,253 individuals |
PGP000856 | Frostdahl H et al. Sci Rep (2024) |
Reported Trait: Chronic liver disease in low physical activity group | — | — | OR per 1-point higher GRSLF: 1.27 [1.05, 1.54] p: 0.016 beta per 1-point higher GRSLF: 0.035 [-0.001, 0.07] p: 0.053 |
age, sex, first 20 genetic principal components, genotyping array, alcohol consumption (g/day), smoking status, Townsend deprivation index | Betas and CI limits were multiplied by 100 and reported as percentages in the manuscript. |
| PPM038267 | PGS019999 (GRSLF) |
PSS013892| European Ancestry| 112,364 individuals |
PGP000856 | Frostdahl H et al. Sci Rep (2024) |
Reported Trait: Chronic liver disease in moderate physical activity group | — | — | OR per 1-point higher GRSLF: 1.13 [1.02, 1.26] p: 0.017 beta per 1-point higher GRSLF: 0.016 [0.002, 0.029] p: 0.023 |
age, sex, first 20 genetic principal components, genotyping array, alcohol consumption (g/day), smoking status, Townsend deprivation index | Betas and CI limits were multiplied by 100 and reported as percentages in the manuscript. |
| PPM038268 | PGS019999 (GRSLF) |
PSS013890| European Ancestry| 98,691 individuals |
PGP000856 | Frostdahl H et al. Sci Rep (2024) |
Reported Trait: Chronic liver disease in high physical activity group | — | — | OR per 1-point higher GRSLF: 1.22 [1.06, 1.4] p: 0.006 beta per 1-point higher GRSLF: 0.015 [0.004, 0.027] p: 0.009 |
age, sex, first 20 genetic principal components, genotyping array, alcohol consumption (g/day), smoking status, Townsend deprivation index | Betas and CI limits were multiplied by 100 and reported as percentages in the manuscript. |
| PPM038253 | PGS019999 (GRSLF) |
PSS013896| European Ancestry| 23,080 individuals |
PGP000856 | Frostdahl H et al. Sci Rep (2024) |
Reported Trait: Liver fat content | — | — | R²: 0.053 Beta per 1-point higher GRSLF: 0.058 [0.052, 0.065] |
age, sex, genotyping array, and population substructure | Effect estimate is per 1-point increase in the unweighted GRS, not per SD. |
| PPM038254 | PGS019999 (GRSLF) |
PSS013894| European Ancestry| 2,855 individuals |
PGP000856 | Frostdahl H et al. Sci Rep (2024) |
Reported Trait: Liver fat content in low physical activity group | — | — | Beta per 1-point higher GRSLF: 0.063 [0.041, 0.084] | genotyping array, first 20 genetic principal components, age, sex, alcohol consumption (g/day), smoking status, Townsend deprivation index | Effect estimate is per 1-point increase in the unweighted GRS, not per SD. |
|
PGS Sample Set ID (PSS) |
Phenotype Definitions and Methods | Participant Follow-up Time | Sample Numbers | Age of Study Participants | Sample Ancestry | Additional Ancestry Description | Cohort(s) | Additional Sample/Cohort Information |
|---|---|---|---|---|---|---|---|---|
| PSS009551 | Hospitalization due to liver cell carcinoma (ICD10 C22.0) | Median = 8.6 years | [
|
— | European | — | UKB | — |
| PSS009552 | Hospitalization due to nonalcoholic fatty liver (ICD10 K76.0) | Median = 8.6 years | [
|
— | European | — | UKB | — |
| PSS009553 | Hospitalization due to other specified inflammatory liver diseases including nonalcoholic steatohepatitis (ICD10 K75.8) | Median = 8.6 years | [
|
— | European | — | UKB | — |
| PSS009554 | Hospitalization or death due to (ICD10; ICD9 codes): cirrhosis (K74.6; 5715), alcoholic cirrhosis or liver damage (K70.3; 5712, 5713), esophageal varices (I85.0,I85.9; 4560, 4561) or portal hypertension (K76.6; 5723) | Median = 8.6 years | [
|
— | European | — | UKB | — |
| PSS001089 | Plasma levels of lipids and lipoproteins were measured by standard enzymatic assays. Hypertension was defined as systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg, or self‐reported antihypertensive treatment. Of the 4,570 individuals, 1,496 had hypertension. | — | 4,570 individuals, 43.0 % Male samples |
Mean = 45.0 years Sd = 11.0 years |
European, African American or Afro-Caribbean, Hispanic or Latin American, Not reported | European = 1,351, African American or Afro-Caribbean = 2,355, Hispanic or Latin American = 743, Not reported = 121 | DaHS | 40.12% sample overlap with this dataset and the dataset used to develop PRS-HFC. |
| PSS001090 | All individuals were identified as being severly obese. Homeostasis model assessment-insulin resistance index was calculated from fasting levels of glucose and insulin. Plasma levels of lipids and lipoproteins were measured by standard enzymatic assays. | — | 3,329 individuals, 30.0 % Male samples |
Mean = 48.0 years Sd = 6.0 years |
European | — | SOS | — |
| PSS001094 | Cases were individuals with liver disease. Of the 1,699 cases, 1,473 had fatty liver disease (FLD) whilst 226 had hepatocellular carcinoma (HCC). Of the 1,473 individuals with FLD, 297 had severe fibrosis and were therefore classified as being within stage 3-4 of FLD. Severe fibrosis was defined in the presence of histological fibrosis F3-F4 (when liver biopsy was available) or in presence of clinical, endoscopic or radiological signs of portal hypertension or cirrhosis, or liver stiffness ≥8.4 kPa evaluated by Fibroscan. Diagnosis of HCC was based on EASL-EORTC Clinical Practice Guidelines. | — | [ ,
57.76 % Male samples |
— | European | — | NR | Cases were obtained from the Nonalcoholic Fatty Liver Disease (NAFLD) Case-Control Cross-Sectional Cohort. |
| PSS001095 | All individuals had liver disease. Of the 158 cases, 72 had cirrhosis whilst 84 had hepatocellular cancer. Diagnosis of HCC was based on EASL-EORTC Clinical Practice Guidelines | — | [ ,
43.59 % Male samples |
— | Not reported | — | NR | — |
| PSS001096 | Cases were individuals with liver disease. Of the 1,628 cases, 1,426 individuals had cirrhosis whilst 202 had hepatocellular cancer (HCC). Cirrhosis was defined as ICD-10 codes I85.0, I85.9, K70.3, K70.4, K72.1, K74.1, K74.2, K74.6, K76.6, K76.7 using hospitalization records (data-field 41270). HCC was defined by combining International Classification of Diseases, Tenth Revision (ICD-10) code C22.0 from both UK cancer registry (data-field 40006), and hospitalization records (data-field 41270). | — | [ ,
46.22 % Male samples |
— | European | — | UKB | — |
| PSS013889 | — | — | 239,308 individuals | — | European | — | UKB | — |
| PSS013893 | — | — | 9,105 individuals, 52.4 % Male samples |
Mean = 55.8 years Sd = 7.6 years |
European | — | UKB | — |
| PSS001099 | All individuals had a body mass index ≥30. Cases were individuals with hepatocellular cancer (HCC). HCC was defined by combining International Classification of Diseases, Tenth Revision (ICD-10) code C22.0 from both UK cancer registry (data-field 40006), and hospitalization records (data-field 41270). | — | [
|
— | European | — | UKB | — |
| PSS013895 | — | — | 11,120 individuals, 48.94 % Male samples |
Mean = 55.5 years Sd = 7.4 years |
European | — | UKB | — |
| PSS001100 | Cases were individuals with hepatocellular cancer (HCC). HCC was defined by combining International Classification of Diseases, Tenth Revision (ICD-10) code C22.0 from both UK cancer registry (data-field 40006), and hospitalization records (data-field 41270). | — | [
|
— | European | — | UKB | — |
| PSS001102 | All individuals had no diagnosis of cirrhosis. Cases were individuals with hepatocellular cancer (HCC). HCC was defined by combining International Classification of Diseases, Tenth Revision (ICD-10) code C22.0 from both UK cancer registry (data-field 40006), and hospitalization records (data-field 41270). | — | [
|
— | European | — | UKB | — |
| PSS013891 | — | — | 28,253 individuals | — | European | — | UKB | — |
| PSS001104 | All individuals had type 2 diabetes (T2D). Diabetes was defined as individuals having either of following criteria: 1) self-reported type 2 or unspecified diabetes (codes 1220 and 1223 in data-field 20002); 2) ICD10 diagnoses codes E11 and E14 (data-field 41270); 3) insulin treatment or use of oral glucose lowering drugs (data-fields 6153, 6177 and 20003); 4) serum glucose level ≥11.1 mmol/L (200mg/dL); 5) HbA1c ≥ 48 mmol/mol (6.5%). Cases were individuals with hepatocellular cancer (HCC). HCC was defined by combining International Classification of Diseases, Tenth Revision (ICD-10) code C22.0 from both UK cancer registry (data-field 40006), and hospitalization records (data-field 41270). | — | [
|
— | European | — | UKB | — |
| PSS013892 | — | — | 112,364 individuals | — | European | — | UKB | — |
| PSS013896 | — | — | 23,080 individuals | — | European | — | UKB | — |
| PSS013894 | — | — | 2,855 individuals, 52.5 % Male samples |
Mean = 54.7 years Sd = 7.2 years |
European | — | UKB | — |
| PSS001114 | Cases were individuals with severe liver disease (SLD). SLD was defined as a composite diagnosis of cirrhosis, decompensated liver disease (i.e., esophageal varices with or without bleeding, portal hypertension, hepatorenal syndrome, liver failure), hepatocellular carcinoma and/or liver transplantation (ICD-10 C22.0, I85.0, I85.9, K70.3, K70.4, K72.1, K72.9, K74.1, K74.2, K74.6, K76.6, K76.7, Z94.4) in any of the aforementioned records. | Median = 9.0 years IQR = [8.3, 9.7] years |
[ ,
45.0 % Male samples |
Mean = 56.5 years Sd = 8.1 years |
European | — | UKB | — |
| PSS001115 | All individuals had diabetes. Cases were individuals with severe liver disease (SLD). SLD was defined as a composite diagnosis of cirrhosis, decompensated liver disease (i.e., esophageal varices with or without bleeding, portal hypertension, hepatorenal syndrome, liver failure), hepatocellular carcinoma and/or liver transplantation (ICD-10 C22.0, I85.0, I85.9, K70.3, K70.4, K72.1, K72.9, K74.1, K74.2, K74.6, K76.6, K76.7, Z94.4) in any of the aforementioned records. | — | [
|
— | European | — | UKB | — |
| PSS001116 | All individuals were classified as obese. Cases were individuals with severe liver disease (SLD). SLD was defined as a composite diagnosis of cirrhosis, decompensated liver disease (i.e., esophageal varices with or without bleeding, portal hypertension, hepatorenal syndrome, liver failure), hepatocellular carcinoma and/or liver transplantation (ICD-10 C22.0, I85.0, I85.9, K70.3, K70.4, K72.1, K72.9, K74.1, K74.2, K74.6, K76.6, K76.7, Z94.4) in any of the aforementioned records. | — | [
|
— | European | — | UKB | — |
| PSS013890 | — | — | 98,691 individuals | — | European | — | UKB | — |